1. Academic Validation
  2. Histone deacetylase inhibitor, AR-42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells

Histone deacetylase inhibitor, AR-42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells

  • J Cell Physiol. 2019 Dec;234(12):22411-22423. doi: 10.1002/jcp.28806.
Sujuan Duan 1 2 Xiaona Gong 3 Xing Liu 4 Wenwen Cui 4 Kaddie Chen 2 Longbing Mao 4 Sun Jun 5 Ruihao Zhou 4 Yi Sang 2 Guofu Huang 1 2
Affiliations

Affiliations

  • 1 Department of Ophthalmology, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • 2 Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • 3 Department of Ophthalmology, Xiangyang First People's Hospital, Xiangyang, China.
  • 4 Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • 5 First Clinical Department, Medical School of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Abstract

Retinoblastoma (RB) is the most common type of intraocular malignant tumor that occurs in childhood. AR-42, a member of a newly discovered class of phenylbutyrate-derived histone deacetylase inhibitors, exerts antitumor effects on many cancers. In the present study, we initially evaluated the effect of AR-42 towards RB cells and explored the underlying mechanism in this disease. Our results found that AR-42 showed powerful antitumor effects at low micromolar concentrations by inhibiting cell viability, blocking cell cycle, stimulating Apoptosis in vitro, and suppressing RB growth in a mouse subcutaneous tumor xenograft model. Furthermore, the Akt/nuclear factor-kappa B signaling pathway was disrupted in Y79 cells treated with AR-42. In conclusion, we propose that AR-42 might be a promising drug treatment for RB.

Keywords

AKT/NF-κB; AR-42; Y79; retinoblastoma.

Figures
Products